Pharmacogenomics of autism spectrum disorder

References

• 1 Association AP. Diagnostic and Statistical Manual of Mental Disorders (5th Edition). American Psychiatric Publishing, VA, USA (2013).
  Google Scholar
• 2 Investigators DDMNSYP; Centers for Disease Control and Prevention (CDC), Prevalence of autism spectrum disorder among children aged 8 years – autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill. Summ. 63(2), 1–21 (2014).
  Google Scholar
• 3 Christensen DL, Baio J, Braun KV et al. Prevalence and characteristics of autism spectrum disorder among children aged 8 years--autism and developmental disabilities monitoring network, 11 sites, United States, 2012. MMWR Surveill. Summ. 65(3), 1–23 (2016).
  MedlineGoogle Scholar
• 4 Johnson CP, Myers SM, Disabilities AAoPCoCW. Identification and evaluation of children with autism spectrum disorders. Pediatrics 120(5), 1183–1215 (2007).
  MedlineGoogle Scholar
• 5 Chen CH, Liao HM, Chen HI et al. Complex genomic variants contribute toward the genetic architecture of autism spectrum disorder. Psychiatr. Genet. 26(2), 95–96 (2016).
  MedlineGoogle Scholar
• 6 Beaudet AL. Autism: highly heritable but not inherited. Nat. Med. 13(5), 534–536 (2007).
  Medline CASGoogle Scholar
• 7 Rosenberg RE, Law JK, Yenokyan G, McGready J, Kaufmann WE, Law PA. Characteristics and concordance of autism spectrum disorders among 277 twin pairs. Arch. Pediatr. Adolesc. Med. 163(10), 907–914 (2009).
  MedlineGoogle Scholar
• 8 De Rubeis S, He X, Goldberg AP et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 515(7526), 209–215 (2014).
  Medline CASGoogle Scholar
• 9 Wang K, Zhang H, Ma D et al. Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature 459(7246), 528–533 (2009).
  Medline CASGoogle Scholar
• 10 Anney R, Klei L, Pinto D et al. A genome-wide scan for common alleles affecting risk for autism. Hum. Mol. Genet. 19(20), 4072–4082 (2010).
  Medline CASGoogle Scholar
• 11 Klei L, Sanders SJ, Murtha MT et al. Common genetic variants, acting additively, are a major source of risk for autism. Mol. Autism 3(1), 9 (2012).
  MedlineGoogle Scholar
• 12 Lee SH, Ripke S, Neale BM et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat. Genet. 45(9), 984–994 (2013).
  Medline CASGoogle Scholar
• 13 Stein JL, Parikshak NN, Geschwind DH. Rare inherited variation in autism: beginning to see the forest and a few trees. Neuron 77(2), 209–211 (2013).
  Medline CASGoogle Scholar
• 14 Hallmayer J, Cleveland S, Torres A et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch. Gen. Psychiatry 68(11), 1095–1102 (2011).
  MedlineGoogle Scholar
• 15 Volkmar F, Siegel M, Woodbury-Smith M et al. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. J. Am. Acad. Child Adolesc. Psychiatry 53(2), 237–257 (2014).
  MedlineGoogle Scholar
• 16 Rosenberg RE, Mandell DS, Farmer JE, Law JK, Marvin AR, Law PA. Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007–2008. J. Autism Dev. Disord. 40(3), 342–351 (2010).
  MedlineGoogle Scholar
• 17 Owen R, Sikich L, Marcus RN et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124(6), 1533–1540 (2009).
  MedlineGoogle Scholar
• 18 Marcus RN, Owen R, Kamen L et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J. Am. Acad. Child Adolesc. Psychiatry 48(11), 1110–1119 (2009).
  MedlineGoogle Scholar
• 19 Curran MP. Aripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile report. CNS Drugs 25(9), 801–802 (2011).
  MedlineGoogle Scholar
• 20 Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. Cochrane Database Syst. Rev. 1, CD005040 (2007).
  Google Scholar
• 21 Reekie J, Hosking SP, Prakash C, Kao KT, Juonala M, Sabin MA. The effect of antidepressants and antipsychotics on weight gain in children and adolescents. Obes. Rev. 16(7), 566–580 (2015).
  Medline CASGoogle Scholar
• 22 Mandell DS, Morales KH, Marcus SC, Stahmer AC, Doshi J, Polsky DE. Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics 121(3), e441–e448 (2008).
  MedlineGoogle Scholar
• 23 Williams K, Brignell A, Randall M, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst. Rev. 8, CD004677 (2013).
  Google Scholar
• 24 King BH, Hollander E, Sikich L et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch. Gen. Psychiatry 66(6), 583–590 (2009).
  Medline CASGoogle Scholar
• 25 Cook EH. Literature review: citalopram efficacy study; interstitial 15q11–q13 duplication mouse. Autism Res. 2, 238–240 (2009).
  Google Scholar
• 26 Hall T, Kriz D, Duvall S, Nguyen-Driver M, Duffield T. Healthcare transition challenges faced by young adults with autism spectrum disorder. Clin. Pharmacol. Ther. 98(6), 573–575 (2015).
  Medline CASGoogle Scholar
• 27 McCracken JT, McGough J, Shah B et al. Risperidone in children with autism and serious behavioral problems. N. Engl. J. Med. 347(5), 314–321 (2002).
  Medline CASGoogle Scholar
• 28 Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch. Pharmacol. 359(2), 147–151 (1999).
  Medline CASGoogle Scholar
• 29 The human cytochrome p450 allele nomenclature database. www.cypalleles.ki.se/cyp2d6.htm.
  Google Scholar
• 30 Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83(2), 234–242 (2008).
  Medline CASGoogle Scholar
• 31 Vanwong N, Ngamsamut N, Hongkaew Y et al. Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels. Drug Metab. Pharmacokinet. 31(2), 156–162 (2016).
  Medline CASGoogle Scholar
• 32 Vanwong N, Ngamsamut N, Medhasi S et al. Impact of CYP2D6 polymorphism on steady-state plasma levels of risperidone and 9-hydroxyrisperidone in thai children and adolescents with autism spectrum disorder. J. Child Adolesc. Psychopharmacol. doi:10.1089/cap.2014.0171 (2016) (Epub ahead of print).
  MedlineGoogle Scholar
• 33 Risperdal^™ package insert. Janssen Pharmaceuticals, Inc, NJ, USA.
  Google Scholar
• 34 Abilify^™ package insert. Otsuka Pharmaceutical Co, Tokyo, Japan.
  Google Scholar
• 35 van der Weide K, van der Weide J. The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients. J. Clin. Psychopharmacol. 35(3), 228–236 (2015).
  Medline CASGoogle Scholar
• 36 Hendset M, Hermann M, Lunde H, Refsum H, Molden E. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur. J. Clin. Pharmacol. 63(12), 1147–1151 (2007).
  Medline CASGoogle Scholar
• 37 Suzuki T, Mihara K, Nakamura A et al. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther. Drug Monit. 36(5), 651–655 (2014).
  Medline CASGoogle Scholar
• 38 Correia CT, Almeida JP, Santos PE et al. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J. 10(5), 418–430 (2010).
  Medline CASGoogle Scholar
• 39 Falkenberg VR, Gurbaxani BM, Unger ER, Rajeevan MS. Functional genomics of serotonin receptor 2A (HTR2A): interaction of polymorphism, methylation, expression and disease association. Neuromolecular Med. 13(1), 66–76 (2011).
  Medline CASGoogle Scholar
• 40 Lundstrom K, Turpin MP. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem. Biophys. Res. Commun. 225(3), 1068–1072 (1996).
  Medline CASGoogle Scholar
• 41 Arranz MJ, Munro J, Sham P et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr. Res. 32(2), 93–99 (1998).
  Medline CASGoogle Scholar
• 42 Hwang R, Zai C, Tiwari A et al. Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J. 10(3), 200–218 (2010).
  Medline CASGoogle Scholar
• 43 Youngster I, Zachor DA, Gabis LV et al. CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study. Dev. Med. Child Neurol. 56(10), 990–994 (2014).
  MedlineGoogle Scholar
• 44 Roke Y, van Harten PN, Franke B, Galesloot TE, Boot AM, Buitelaar JK. The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys. Pharmacogenet. Genomics 23(9), 487–493 (2013).
  Medline CASGoogle Scholar
• 45 Sukasem C, Hongkaew Y, Ngamsamut N et al. Impact of pharmacogenetic markers of CYP2D6 and DRD2 on prolactin response in risperidone-treated thai children and adolescents with autism spectrum disorders. J. Clin. Psychopharmacol. 36(2), 141–146 (2016).
  Medline CASGoogle Scholar
• 46 Anderson GM, Scahill L, McCracken JT et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol. Psychiatry 61(4), 545–550 (2007).
  Medline CASGoogle Scholar
• 47 Hoekstra PJ, Troost PW, Lahuis BE et al. Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene. J. Child Adolesc. Psychopharmacol. 20(6), 473–477 (2010).
  MedlineGoogle Scholar
• 48 Nurmi EL, Spilman SL, Whelan F et al. Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. Transl. Psychiatry 3, e274 (2013).
  Medline CASGoogle Scholar
• 49 Lit L, Sharp FR, Bertoglio K et al. Gene expression in blood is associated with risperidone response in children with autism spectrum disorders. Pharmacogenomics J. 12(5), 368–371 (2012).
  Medline CASGoogle Scholar
• 50 Sugie Y, Sugie H, Fukuda T et al. Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism. J. Autism Dev. Disord. 35(3), 377–385 (2005).
  MedlineGoogle Scholar
• 51 Bishop JR, Najjar F, Rubin LH et al. Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. Pharmacogenet. Genomics 25(11), 548–554 (2015).
  Medline CASGoogle Scholar
• 52 Owley T, Brune CW, Salt J et al. A pharmacogenetic study of escitalopram in autism spectrum disorders. Autism Res. 3(1), 1–7 (2010).
  MedlineGoogle Scholar
• 53 Najjar F, Owley T, Mosconi MW et al. Pharmacogenetic study of serotonin transporter and 5HT2A genotypes in autism. J. Child Adolesc. Psychopharmacol. 25(6), 467–474 (2015).
  Medline CASGoogle Scholar
• 54 McCracken JT, Badashova KK, Posey DJ et al. Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders. Pharmacogenomics J. 14(3), 295–302 (2014).
  Medline CASGoogle Scholar
• 55 De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 26(9), 733–759 (2012).
  Medline CASGoogle Scholar
• 56 MacNeil RR, Müller DJ. Genetics of common antipsychotic-induced adverse effects. Mol. Neuropsychiatry 2(2), 61–78 (2016).
  Medline CASGoogle Scholar
• 57 Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J. Child Adolesc. Psychopharmacol. 21(6), 517–535 (2011).
  Medline CASGoogle Scholar
• 58 Sicard MN, Zai CC, Tiwari AK et al. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics 11(11), 1561–1571 (2010).
  CASGoogle Scholar
• 59 Wallace TJ, Zai CC, Brandl EJ, Müller DJ. Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain. Pharmgenomics Pers. Med. 4, 83–93 (2011).
  Medline CASGoogle Scholar
• 60 Zhang JP, Lencz T, Zhang RX et al. Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis. Schizophr. Bull. 42(6), 1418–1437 (2016).
  MedlineGoogle Scholar
• 61 Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28(Suppl. 1), 53–67 (2003).
  Medline CASGoogle Scholar
• 62 Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J. Clin. Psychopharmacol. 19(1), 57–61 (1999).
  Medline CASGoogle Scholar
• 63 Naidoo U, Goff DC, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 28(Suppl. 2), 97–108 (2003).
  Medline CASGoogle Scholar
• 64 Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. J. Psychopharmacol. 22(Suppl. 2), 12–19 (2008).
  MedlineGoogle Scholar
• 65 Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum. Mol. Genet. 6(4), 577–582 (1997).
  Medline CASGoogle Scholar
• 66 Jönsson EG, Nöthen MM, Grünhage F et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry 4(3), 290–296 (1999).
  Medline CASGoogle Scholar
• 67 Cabaleiro T, Ochoa D, López-Rodríguez R et al. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. Hum. Psychopharmacol. 29(5), 459–469 (2014).
  Medline CASGoogle Scholar
• 68 Ngamsamut N, Hongkaew Y, Vanwong N et al. 9-hydroxyrisperidone-induced hyperprolactinaemia in Thai children and adolescents with autism spectrum disorder. Basic Clin. Pharmacol. Toxicol. 119(3), 267–272 (2016).
  Medline CASGoogle Scholar
• 69 Heils A, Teufel A, Petri S et al. Allelic variation of human serotonin transporter gene expression. J. Neurochem. 66(6), 2621–2624 (1996).
  Medline CASGoogle Scholar
• 70 Hu XZ, Lipsky RH, Zhu G et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am. J. Hum. Genet. 78(5), 815–826 (2006).
  Medline CASGoogle Scholar
• 71 Wendland JR, Moya PR, Kruse MR et al. A novel, putative gain-of-function haplotype at SLC6A4 associates with obsessive-compulsive disorder. Hum. Mol. Genet. 17(5), 717–723 (2008).
  Medline CASGoogle Scholar
• 72 Harfterkamp M, Buitelaar JK, Minderaa RB, van de Loo-Neus G, van der Gaag RJ, Hoekstra PJ. Atomoxetine in autism spectrum disorder: no effects on social functioning; some beneficial effects on stereotyped behaviors, inappropriate speech, and fear of change. J. Child Adolesc. Psychopharmacol. 24(9), 481–485 (2014).
  Medline CASGoogle Scholar
• 73 Brown JT, Abdel-Rahman SM, van Haandel L, Gaedigk A, Lin YS, Leeder JS. Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. Clin. Pharmacol. Ther. 99(6), 642–650 (2016).
  Medline CASGoogle Scholar